KayoThera
Seattle, US · Founded 2019 · 2 known investors
Kayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology. The company is led by an experienced management team supported by scientific and clinical advisory boards.
BiotechHealthtech
Founders & leadership
KayoThera was founded in 2019 by Mark Esposito and Yibin Kang.
ME
Mark EspositoCSO, Co-Founder and Board Member
YK
Yibin KangChair, Scientific Advisory Board and Co-Founder
TL
Thong LeExecutive
KM
Kendall MohlerExecutive
TQ
Thong Q. LePresident and CEO, Board Member
IH
Ian HowesChief Financial Officer
MK
Merika KodayCOO and Board Member
Investors · 2
Competitors · 4
by search overlapCoya Therapeutics35 shared keywords
SonoThera19 shared keywordsSonoThera develops a nonviral, ultrasound-mediated gene-delivery platform (RIPPLE) for targeted, redosable genetic medicines across organ systems, with preclinical programs in indications such as Duchenne Muscular Dystrophy, ADPKD, Alport Syndrome, and Hemophilia A. The company builds in-house payload design and manufacturing for DNA, RNA, siRNA, and gene-editing modalities.
AltaThera Pharmaceuticals19 shared keywordsAltaThera Pharmaceuticals develops hospital-use intravenous drug therapies for treating cardiovascular conditions such as atrial fibrillation, atrial flutter, and ventricular arrhythmias in adult and pediatric patients. Its intravenous approach to antiarrhythmic initiation aims to enable faster therapeutic assessment and more precise dosing for physicians in hospital settings.
Kite Pharma18 shared keywordsKite Pharma develops CAR T-cell therapies for cancer patients, engineering the immune system's cells to target and attack cancer. Each therapy is individualized per patient through a multi-step manufacturing process.
Companies competing with KayoThera for the same Google search keywords, organic and paid, via search-intersection analysis.
Reported raises · per SEC filings
Form D private placements$11.2M disclosed across 2 rounds · 2019–2022
▶$10.5MraisedJul 2023 · 14 investors · OtherRule 506(b)
▶$10.5MraisedJul 2023 · 14 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Thong LeExecutive Officer, Director
- Mark EspositoExecutive Officer, Director
- Kendall MohlerExecutive Officer, Director
- Ian HowesExecutive Officer
- Offering amount
- $10.9M
- Amount sold
- $10.5M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$750KraisedJun 2019 · 1 investors · OtherRule 506(b)
▶$750KraisedJun 2019 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Mark EspositoExecutive Officer, Director
- Yibin KangDirector
- George F. HeinrichDirector
- James M. GolubieskiDirector
- Offering amount
- $750K
- Amount sold
- $750K
- First sale
- May 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does KayoThera do?
- Kayo Therapeutics is a biotechnology company developing therapeutics, with a scientific and clinical focus that includes areas such as metabolic disease and oncology. The company is led by an experienced management team supported by scientific and clinical advisory boards.
- Who founded KayoThera?
- KayoThera was founded by Mark Esposito, Yibin Kang in 2019.
- Who are KayoThera's investors?
- KayoThera's investors include 7G BioVentures, Foundation Venture Capital Group, LLC.
- How much funding has KayoThera raised?
- KayoThera has disclosed $11.2M raised across 2 rounds.
- Where is KayoThera headquartered?
- KayoThera is headquartered in Seattle, US.